Cervical clear cell adenocarcinoma

Summary

Cervical clear cell adenocarcinoma (MONDO:0006135) is a disease and 1 clinical trial. Top therapeutic interventions include lorigerlimab. A subtype of clear cell adenocarcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	cervical clear cell adenocarcinoma
Mondo ID	MONDO:0006135
EFO	EFO:1000163
DOID	DOID:5303
NCIT	C6344
UMLS	C1332912
MedGen	234113
GARD	0024304
Anatomy (UBERON)	UBERON:0000002
Is cancer (heuristic)	no

Also known as: cervical clear cell adenocarcinoma · cervical clear cell carcinoma · cervix clear cell adenocarcinoma · cervix clear cell carcinoma · cervix uteri clear cell adenocarcinoma · cervix uteri clear cell carcinoma · clear cell adenocarcinoma of cervix · clear cell adenocarcinoma of cervix uteri · clear cell adenocarcinoma of the cervix · clear cell adenocarcinoma of the cervix uteri · clear cell adenocarcinoma of the uterine cervix · clear cell adenocarcinoma of uterine cervix · clear cell carcinoma of cervix · clear cell carcinoma of cervix uteri · clear cell carcinoma of the cervix · clear cell carcinoma of the cervix uteri · clear cell carcinoma of the uterine cervix · clear cell carcinoma of uterine cervix · uterine cervix clear cell adenocarcinoma · uterine cervix clear cell carcinoma

Data availability: 2 cell lines.

Disease family

This is a subtype of clear cell adenocarcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › adenocarcinoma › clear cell adenocarcinoma › cervical clear cell adenocarcinoma

Related subtypes (10): hepatocellular clear cell carcinoma, fallopian tube clear cell adenocarcinoma, bladder clear cell adenocarcinoma, urethra clear cell adenocarcinoma, glycogen-rich clear cell breast carcinoma, extrahepatic bile duct clear cell adenocarcinoma, clear cell renal carcinoma, ovarian clear cell adenocarcinoma, endometrial clear cell adenocarcinoma, hidradenocarcinoma

Subtypes (1): uterine ligament clear cell adenocarcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06730347	PHASE2	RECRUITING	A Study of Lorigerlimab in Participants With Advanced Solid Tumors

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
LORIGERLIMAB	2	1